Terminated NA INTERVENTIONAL 1-arm NCT02720796

Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma

A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX or TumorGraft) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma

Sponsor: Champions Oncology

Conditions Sarcoma

Interventions PDX drug sensitivity testing

Updated 6 times since 2017 Last updated: Oct 5, 2017 Started: Nov 30, 2015 Primary completion: Nov 30, 2017 Completion: Nov 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment barriers

Other Sarcoma trials with similar outcome

Browse all Sarcoma trials

This NA trial investigates Sarcoma and is currently terminated or withdrawn. Champions Oncology leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Oct 2017 — Jun 2018 [monthly]

Terminated NA

Status: Recruiting → Terminated

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Recruiting NA

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Champions Oncology
Mount Sinai Hospital, Canada

Data source: Champions Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada